We're happy to announce Boris Bernhardt as the new Associate Leader of Healthy Brains, Healthy Lives (HBHL) Research Theme 1: Neuroinformatics and Computational Modeling.
HBHL's Research Theme 1 Associate Leader plays an essential role in HBHL’s governance and decision-making structure. They also provide input to HBHL's strategic direction, including the development of funding initiatives and activities aimed at reaching HBHL’s goals.
Researchers classify Alzheimer’s progression and subtypes for a personalized approach to the disease
Alzheimer’s disease is a disorder characterized by abnormalities in several different biological areas.
Neurotransmitters are chemicals brain cells use to communicate. They work together with matching receptors on the cell surface to drive brain activity. However, we don’t fully understand how the distribution of these receptors varies region by region throughout the brain, nor what effect they have on brain function.
HBHL is partnering with McGill’s Branches initiative on a second round of the extremely successful
Neural correlates of social cognitive deficits in schizophrenia patients with and without cannabis use
What is the link between substance use and psychosis? Is there a higher chance to develop psychotic disorders for people who use cannabis?
Dr. Rachel Rabin, HBHL-funded researcher at The Neuro, is working to understand the neurocognitive and social cognitive dysfunction in individuals with substance use disorders.
The aim of her study is to help identify therapeutic targets to improve treatments for individuals suffering from schizophrenia and/or cannabis addictions.
What would be possible if there were a tool like Google Maps for the brain? On October 6, HBHL-funded researchers at The Neuro published work in Nature Methods that takes a big step towards making this idea a reality. This effort comes out of the Helmholtz International BigBrain Analytics & Learning Laboratory (HIBALL) initiative combining neuroscience and artificial intelligence to build highly detailed 3D models of the brain at the cellular level.
We're happy to announce Blake Richards as the new Leader of Healthy Brains, Healthy Lives (HBHL) Research Theme 1: Neuroinformatics and Computational Modelling.
HBHL's Theme 1 Leader plays an essential role in HBHL’s governance and decision-making structure. They also provide critical guidance to HBHL's strategic research priorities, building and endorsing activities and funding initiatives aimed at reaching HBHL’s goals.
On May 19 and 20, Healthy Brains, Healthy Lives (HBHL) welcomed over 150 attendees to the first HBHL Symposium since 2019. Held at the Jeanne Timmins Amphitheatre at the Neuro (Montreal Neurological Institute-Hospital), the HBHL Symposium 2022 featured two days of talks and networking opportunities.
Earlier this year, the Government of Canada and its partners announced that they will invest $31.1 million over six years to support the training and development of students and early career researchers. The Health Research Training Platform (HRTP) will form 17 collaborative health research teams of participants across Canada with the goal of increasing their career prospects and building on Canadian research capacity at large.
HBHL is proud to officially announce the 10 winners of the third round of HBHL Ignite grants. The winning principle investigators and their respective projects are:
An HBHL-funded lab at the Douglas Research Centre, led by Martin Lepage, Professor of Psychiatry at McGill University and Deputy Scientific Director at the Douglas, has recently published a study in JAMA Psychiatry to determine the effectiveness of metacognitive training for psychosis (MCT) in treating individuals living with schizophrenia.
A team of researchers from The Neuro (Montreal Neurological Institute-Hospital) and the Department of Biomedical Engineering of McGill University, the Broad Institute at Harvard/MIT, SUNY Downstate Health Sciences University and Mila – Quebec Artificial Intelligence Institute have shown how drug-induced changes in subjective awareness are linked to specific neurotransmitter receptor systems in the largest study of its kind on psychedelics and the brain, funded by HBHL.
Neurosphere involved in a new project with Neurasic Therapeutics, CQDM and Louise and Alan Edwards Foundation
NeuroSphere is pleased to continue to support Neurasic Therapeutics and Dr. Philippe Séguéla since our involvement in the launch of Neurasic therapeutics in 2020 and announce a new $965,000 collaboration between Neurasic Therapeutics, CQDM, the Louise and Alan Edwards Foundation, and Neurosphere.
Dear Healthy Brains, Healthy Lives Community,